Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Home / News / BioBlast™ Archive

BIOSIMILARS UPDATES

Our BioBlast™ Archive

Explore biologics and biosimilars news updates (BioBlast®) at Pearce IP

Pearce IP BioBlast w/e 12 April 2024

12 APR 2024 | US | Six Regeneron Aflibercept US Patent Infringement Actions to be Centralized in West Virginia On 11 April 2024, the United States Judicial Panel on Multijurisdictional Litigation ruled that patent infringement actions brought by...

Pearce IP BioBlast w/e 05 April 2024

05 APR 2024 | Samsung Bioepis Commences Phase 3 Trials for Keytruda® Biosimilar On 5 April 2024, Samsung Bioepis announced the commencement of Phase 3 clinical trials for SB27, biosimilar to MSD’s Keytruda® (pembrolizumab) in patients with...

Pearce IP BioBlast w/e 29 March 2024

28 MAR 2024 | US | Celltrion Launches US Pediatric High Concentration Adalimumab Biosimilar On 28 March 2024, the Korea IT Times reported the US launch of Celltrion’s pediatric 20mg Yuflyma®, biosimilar to AbbVie’s Humira® (adalimumab), for the...

Pearce IP BioBlast w/e 22 March 2024

22 MAR 2024 | AU | Samsung Bioepis Seeks to Revoke Janssen’s Stelara® (ustekinumab) Patents in Australian Court On 22 March 2024, the first case management hearing was held before Justice Nicholas in the Federal Court of Australia, Sydney, in...

Pearce IP BioBlast w/e 15 March 2024

15 MAR 2024 | AU | November 2023 PBAC Public Summary Documents Feature Biopharma On 15 March 2024, the Australian Department of Health and Aged Care published the public summary documents considered at the November 2023 PBAC meeting. Decisions...

Pearce IP BioBlast w/e 8 March 2024

9 MAR 2024  US | Samsung Bioepis Presents Interchangeability Updates for its Adalimumab and Ustekinumab Biosimilars at AAD On 9 March 2024, Samsung Bioepis presented two papers of study results for its immunology portfolio at the 2024 American...

Pearce IP BioBlast w/e 4 March 2024

1 MAR 2024 | AU | Authorities raid Como Compounding Pharmacy in Melbourne and Seize Semaglutide The Australian Financial Review reported that on 1 March 2024 TGA investigators raided Como Compounding Pharmacy in Melbourne and seized ‘off-brand’...

Pearce IP BioBlast w/e 23 Feb 2024

23 FEB 2024 | EU | Samsung Bioepis Presented Study Results for ustekinumab SB17, Biosimilar to Janssen’s Stelara®, at ECCO On 23 February 2024, Samsung Bioepis presented two new study results for ustekinumab SB17 (biosimilar to Janssen’s...

Meet our BioBlast™ authors

Naomi Pearce & Emily Bristow

Naomi Pearce & Emily Bristow

Naomi and Emily author the weekly BioBlast™ update, ensuring that everyone is kept up to date with the latest happenings within the biosimilars industry.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.